Get the Stockscreener App
59.66
1.50%
0.88
After Hours:
59.66
Ani Pharmaceuticals Inc stock is traded at $59.66, with a volume of 263.01K.
It is up +1.50% in the last 24 hours and down -6.42% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$58.78
Open:
$58.7
24h Volume:
263.01K
Relative Volume:
0.77
Market Cap:
$1.24B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
-124.29
EPS:
-0.48
Net Cash Flow:
$100.45M
1W Performance:
-0.70%
1M Performance:
-6.42%
6M Performance:
-13.70%
1Y Performance:
+2.76%
1-Day Range:
$58.70
$60.19
1-Week Range:
$57.10
$60.92
52-Week Range:
$48.20
$70.81
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 8.3% in September - MarketBeat
Maverick Capital Ltd. Purchases 13,926 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? - Yahoo Finance
Drugs for Arrhythmia Market Demand and Business Outlook | Sanofi, Boehringer Ingelheim Pharmaceuticals, Inc, ANI Pharmaceuticals – Cauverynews - Cauverynews
ANI Pharmaceuticals launches generic Ketoconazole Shampoo By Investing.com - Investing.com Canada
ANI Pharmaceuticals launches generic Ketoconazole Shampoo - Investing.com
ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% - The Manila Times
ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% - GlobeNewswire
ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% - StockTitan
American Century Companies Inc. Purchases 49,717 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Quotes, Forecast and News Summary - Benzinga
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal - Benzinga
Renaissance Technologies LLC Raises Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Q3 2024 EPS Estimates for ANI Pharmaceuticals, Inc. Lifted by Capital One Financial (NASDAQ:ANIP) - MarketBeat
Rubric Capital Management LP Decreases Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Rubric Capital Management LP Sells 354,733 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals completes acquisition of Alimera Sciences - Investing.com
Q3 2024 Earnings Forecast for ANI Pharmaceuticals, Inc. Issued By HC Wainwright (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) PT Raised to $83.00 at Raymond James - MarketBeat
ANI Pharmaceuticals shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
ANI Pharmaceuticals (NASDAQ:ANIP) Receives "Buy" Rating from HC Wainwright - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Trading 5.3% Higher - MarketBeat
Alimera Sciences completes merger with ANI Pharmaceuticals - Investing.com India
Alimera Sciences completes merger with ANI Pharmaceuticals By Investing.com - Investing.com Australia
In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals - Benzinga
Alimera Sciences completes merger with ANI Pharmaceuticals By Investing.com - Investing.com Canada
ANI Pharmaceuticals finalizes acquisition of Alimera Sciences - Investing.com
Ani Pharmaceuticals executive sells shares worth over $14k By Investing.com - Investing.com Australia
Alimera Sciences completes merger with ANI Pharmaceuticals - Investing.com
Ani Pharmaceuticals executive sells shares worth over $14k By Investing.com - Investing.com Canada
Ani Pharmaceuticals executive sells shares worth over $14k - Investing.com
Ani Pharmaceuticals executive sells shares worth over $14k By Investing.com - Investing.com UK
Alimera Sciences completes merger with ANI Pharmaceuticals By Investing.com - Investing.com UK
ANI Pharmaceuticals completes acquisition of Alimera Sciences - TipRanks
ANI Pharmaceuticals completes purchase of Alimera Sciences (NASDAQ:ALIM) - Seeking Alpha
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences - GlobeNewswire
ANI Pharmaceuticals, Alimera Sciences deal set to close Monday - MSN
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences - Benzinga
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences - StockTitan
ANI Pharmaceuticals finalizes acquisition of Alimera Sciences - Investing.com India
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences - StockTitan
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences - GlobeNewswire
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences - EIN News
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Expected to Post FY2024 Earnings of $3.45 Per Share - Defense World
ANI Pharmaceuticals, Inc. to Post FY2024 Earnings of $3.45 Per Share, Capital One Financial Forecasts (NASDAQ:ANIP) - MarketBeat
Quest Partners LLC Invests $261,000 in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Large Increase in Short Interest - MarketBeat
ANI Pharmaceuticals Inc [ANIP] Records 200-Day SMA of $61.05 - Knox Daily
Balance Sheet Insights: ANI Pharmaceuticals Inc (ANIP)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Natixis Advisors LLC Purchases Shares of 11,639 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):